Tracked deals
576
576 tracked deals across 2011-2026.
Tracked deals
576
576 tracked deals across 2011-2026.
Buyer mix
Mixed buyer set
471 strategic · 265 pe
Top trend
Volume peaked in 2022
124 tracked deals announced in 2022.
Primary Insight
Build a buyer list for your Healthcare Services deal
Find buyers actively acquiring healthcare services companies.
Find buyers like these for your dealBuyer Snapshot
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| HCAP Partners | 7 | Southern California-based private equity and mezzanine de... | PE |
| The Stepping Stones Group | 7 | National provider of therapeutic, behavioral, autism, nur... | Strategic (PE-backed) |
| Akeso Occupational Health | 6 | Operator of occupational medicine clinic groups focused o... | Strategic (PE-backed) |
| Great Point Partners | 5 | Healthcare-focused private equity firm that provides grow... | PE |
| NMS Capital | 5 | New York-headquartered private investment firm focused on... | PE |
| Spine & Sport Physical Therapy | 5 | Operator of outpatient physical therapy clinics in Southe... | Strategic (PE-backed) |
| Agile Occupational Medicine | 4 | Operator of occupational medicine clinics focused on work... | Strategic |
| FFL Partners | 4 | San Francisco-based private equity firm focused on growth... | PE |
| Gryphon Investors | 4 | Middle-market private investment firm focused on growth i... | PE |
| Headlands Research | 4 | Globally integrated clinical trial site organization oper... | Strategic (PE-backed) |
Last 10 years
Supporting Data
Veracyte, Inc. announced it will acquire Convergent Genomics to add its UroAmp platform, including proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s cancer diagnostics portfolio. The deal is expected to strengthen Veracyte’s bladder cancer offerings by adding a differentiated, urine-based approach for therapy response monitoring and post-treatment surveillance.
Apple acquired Sonera, a California-based company developing non-invasive magnetic sensors to measure neural and muscular signals. The technology could support future Apple health monitoring, accessibility, prosthetics, and brain-computer interface-style interactions, potentially via devices like the Apple Watch.
LeanTaaS acquired Aidin to expand its healthcare capacity and patient flow platform by combining inpatient flow intelligence with care-transition coordination workflows. The combined solution targets improved discharge readiness, reduced avoidable hospital days, and faster placement into post-acute care settings.
VetnCare, a Northern California operator of veterinary hospitals, announced it has acquired Geary Veterinary Hospital, a longstanding veterinary practice in Walnut Creek, California. The deal expands VetnCare’s presence in the East Bay and aligns with its strategy of partnering with locally rooted, clinician-led hospitals.
Imagenet, a healthcare operations technology partner for payers, acquired Analytica Consulting, a California-based data consulting firm specializing in data engineering, analytics, and AI. The deal expands Imagenet’s data and AI capabilities to help healthcare clients turn operational data into actionable intelligence and measurable outcomes.
BioMarin Pharmaceutical entered into a definitive agreement to acquire Alesta Therapeutics to obtain ALE1, Alesta’s lead clinical-stage oral small-molecule program for hypophosphatasia (HPP). BioMarin will pay $275 million upfront plus up to $215 million in development and regulatory milestone payments, and it expects to close the transaction following a planned spinout of all non-ALE1 assets by Alesta.
Westcliff University acquired Pacific College, a private nursing school in Costa Mesa, California. The deal expands Westcliff’s healthcare education footprint in Southern California by combining Pacific College’s nursing programs with Westcliff’s broader academic network and its newly launched College of Nursing in Corona.
iRhythm Holdings (Nasdaq: IRTC) entered into a definitive agreement to acquire VitalConnect, a privately held wearable biosensor and ambulatory cardiac monitoring company, for total consideration of about $287.5 million. The deal includes approximately $237.5 million in cash and about $50 million in iRhythm common stock, and is expected to close by the end of 2026 subject to customary conditions.
Craftech Holdco, a portfolio company of Sage Park, acquired Balda C. Brewer (BCB), an Ontario, California-based contract manufacturing injection molding subsidiary, from Stevanato Group S.p.A. The deal expands the combined platform’s medical cleanroom injection molding capabilities and manufacturing footprint across the United States and Mexico.
Hinge Health signed a definitive agreement to acquire virtual-first digestive healthcare provider Cylinder Health, Inc. for $105 million in cash. The deal is expected to close in Q3 2026 and will support Hinge Health’s integrated Gastrointestinal (GI) Care Program launching in 2027.
Quasar Medical, a contract development and manufacturing organization (CDMO) for minimally invasive medical devices, announced the acquisition of Medres International’s Nitinol Design and Development Center in San Diego, California. The transaction expands Quasar’s advanced nitinol design, development, and manufacturing capabilities and integrates the new site into Quasar’s global engineering and production network.
Physician Growth Partners (PGP) served as exclusive financial advisor to Golden Gate Urology in its partnership with Unio Specialty Care, a portfolio company of Unio Health Partners. Unio Specialty Care delivers urology along with gastroenterology and radiation oncology across California.
Clarion Partners acquired Clearwater at Sonoma Hills, a 94-unit senior living community in Rohnert Park, California, expanding its presence in Northern California’s senior housing market. Clearwater Living will continue as the property’s operating partner following the transaction.
Apex Infusion entered into a definitive agreement to partner with private equity firm SkyKnight Capital to support the company’s next phase of growth. Apex’s clinician-led management team will retain a significant ownership stake and continue to lead, while FFL Partners will remain a minority investor.
Tempus AI has entered into a definitive agreement to acquire Personalis in a transaction with an enterprise value of approximately $1.5 billion (net of Tempus’ existing stake). Personalis shareholders will receive $16.25 per share, with consideration primarily structured as Tempus stock and Tempus having the option to pay up to 50% in cash. The deal is expected to close in late 2026 or early 2027, subject to shareholder approval, regulatory clearances, and customary closing conditions.
VetnCare, a Northern California community of veterinary hospitals backed by Great Point Partners, acquired Holistic Veterinary Care in an add-on transaction. The Oakland-based hospital, founded in 2009 and focused on integrative and rehabilitative animal medicine, will be integrated into the VetnCare network, with founder Dr. Gary Richter staying on as Clinical Director and practicing veterinarian.
ClearOne announced a definitive agreement and plan of merger with Vivani Medical’s wholly owned subsidiary Cortigent. Upon closing, Cortigent will become a wholly owned subsidiary of ClearOne, and the combined company will be renamed Cortigent Holdings (Nasdaq: CRGT).
PharmaResearch signed an agreement to acquire Cosmetic Group USA (CG USA), a U.S. cosmetics OEM and ODM manufacturer, to strengthen its North America localization strategy. The deal is intended to build a local manufacturing and supply chain base for REJURAN Cosmetics, supporting growth across the United States and future expansion into Canada and broader Americas.
Headlands Research announced the acquisition of Clinical Trials Research (CTR), a privately owned clinical research organization with locations in Sacramento and Lincoln, California. The sites will be rebranded as Headlands Research – Sacramento and Headlands Research – CTR Lincoln, expanding Headlands’ California presence and cardiometabolic therapeutic area capabilities. Financial terms were not disclosed.
GRAIL, Inc. announced the closing of its previously announced $110 million equity financing with Samsung affiliates, including Samsung C&T Corporation. The Samsung entities purchased shares of GRAIL common stock at $70.05 per share to support GRAIL’s growth, cash runway, regulatory approval and reimbursement efforts for Galleri in the United States, and international expansion—particularly in Asia including South Korea.
Biogen entered into a definitive agreement to acquire RayThera, a private immunology-focused biotechnology company, for total consideration of up to $1 billion driven by an upfront payment plus clinical and regulatory milestone payments. The deal is expected to close in the third quarter of 2026, with Biogen taking over development, manufacturing, and global commercialization of RayThera’s small-molecule anti-inflammatory assets.
Clarify Health completed its acquisition of Loyal Health Holdings, creating a closed-loop network intelligence and patient activation platform. The combined platform unifies Clarify’s Meridian referral intelligence with Loyal’s Care Activation Platform to identify where patients need care, activate them to the right provider, and measure outcomes.
Micro Imaging Technology (MIT), a California-based public company, announced its acquisition of Cellmyx to expand its regenerative medicine and medical aesthetics portfolio. The deal combines Cellmyx’s autologous adipose grafting and transfer technologies (IntelliFat BOD) with MIT’s recently acquired SaltMed/SaltFacial to broaden manufacturing capabilities and product offerings for orthopedic, plastic, and cosmetic surgery use cases.
Photocure ASA has agreed to acquire Vesica Health for $30.5 million (cash and stock), including a prior $3.0 million equity investment made in Q1 2026. The deal adds AssureMDx, a noninvasive urine-based multi-omic test for early detection and risk stratification of bladder cancer in hematuria patients, to Photocure’s bladder cancer diagnostics portfolio.
Hidden River Strategic Capital invested in Northstar Senior Living in connection with Northstar’s merger with Alta Senior Living. The merged company will operate under the Northstar Senior Living brand, with Northstar’s team running day-to-day operations and Alta CEO Doug Brawn serving as Board Chair.
Discovery Behavioral Health (DBH) entered a major restructuring after defaulting on roughly $280 million of debt, following a dispute over its debt-to-earnings calculations. Lenders led by HPS Investment Partners and Capital One seized control, ousting the board and CEO and effectively converting debt into ownership, with a new CEO (Pete Clarke) introduced in the subsequent announcement.
The Radoff-JEC Group (led by Bradley L. Radoff and Michael Torok) issued an open letter urging Seer, Inc. to reevaluate its rejected acquisition proposal and to initiate a strategic review process. The group reaffirms a fully financed proposal to acquire Seer for $2.40 per share in cash (a 42% premium to the unaffected share price) plus a contingent value right (CVR) that would provide stockholders with 80% of the net proceeds from certain asset dispositions.
Swoop, a healthcare engagement platform backed by New Mountain Capital, announced the acquisition of Nimble, a prescription management platform for independent pharmacies across all 50 states. The deal expands Swoop from engagement and omnichannel activation into prescription fulfillment and medication adherence using privacy-safe pharmacy data and signals.
Liminatus Pharma has entered into a definitive merger agreement to acquire InnocsAI via a newly formed wholly owned Delaware subsidiary. The deal values InnocsAI at approximately $320 million, with InnocsAI’s members receiving 1.6 billion Liminatus shares at $0.20 per share plus contingent value rights (CVRs) tied to 20% of future net proceeds from certain strategic transactions involving the acquired assets.
InSphero AG announced it has acquired PhenoVista Biosciences, Inc., a San Diego-based contract research organization specializing in high-content imaging and phenotypic assay technologies. The deal is intended to expand InSphero’s advanced 3D, cell-based assay and imaging capabilities and accelerate adoption of more predictive, human-relevant drug discovery and toxicology workflows.
Ethos, a claims investigation and medical management firm, acquired Definiti Comp Solutions, a national provider of workers' compensation medical cost containment services. The deal is intended to strengthen Ethos' national bill review capabilities and broaden cost containment solutions for carriers, TPAs, self-insured employers, and public sector clients.
NeuroVision Imaging Inc. acquired Durin Life Sciences Inc. to create an integrated platform for earlier detection and longitudinal management of neurodegenerative diseases. The deal combines Durin’s blood-based biomarker diagnostics (Duritect) with NeuroVision’s retinal imaging, telehealth infrastructure, and BrainHealth.net patient engagement ecosystem.
Medit, a digital dentistry company, has completed the acquisition of Progressive Orthodontics through its U.S. subsidiary Medit USA Inc. The deal also launches Medit’s Global Orthodontic Business Division to combine Medit’s digital orthodontic software and 3D scanning technology with Progressive Orthodontics’ clinical education network.
Treble Health, a telehealth-focused tinnitus and audiology provider, acquired Silicon Valley Hearing, a medical-model audiology practice in Los Gatos, California. The deal expands Treble Health’s in-person services to the San Francisco Bay Area by adding Silicon Valley Hearing’s clinical team and establishing a Los Gatos care location.
Tot Squad announced it is acquiring Robyn, an AI-powered maternal health startup that acts as an always-on doula trained on de-identified conversations between doulas and parents. Robyn will be integrated into Tot Squad’s platform, alongside its registry-based support offerings and marketplace for in-person doula and related services.
LEO Pharma has entered into a definitive agreement to acquire Replay, a gene therapy company developing treatments for rare genetic dermatological conditions. The acquisition adds Replay’s high-payload herpes simplex virus (HSV) delivery vector platform to LEO Pharma’s dermatology pipeline, with the lead program targeting dystrophic epidermolysis bullosa (DEB) currently in preclinical studies.
Nationwide Medical, a provider of specialized respiratory care and home health solutions, announced the acquisition of Dynamic Healthcare Services (DHS). The deal is intended to expand Nationwide Medical’s home respiratory and sleep therapy support and broaden its regional footprint in Pennsylvania, New Jersey, and surrounding markets.
CareDx entered into a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company, for $160 million upfront cash plus up to $100 million in revenue-based milestones. The acquisition extends CareDx’s precision medicine testing strategy into specialty oncology via Naveris’ NavDx liquid biopsy platform for viral-mediated cancers and MRD surveillance, with an anticipated close in Q3 2026 subject to customary conditions.
LEEF Brands, Inc. entered into an agreement to acquire Standard Holdings, Inc., the parent company of HIMALAYA Vapor, a California-based cannabis concentrates brand. The deal is valued at approximately US$2.5 million, consisting of 13,688,000 LEEF common shares (including management incentive shares) plus warrants with an aggregate value of US$100,000.
TriNet completed its previously disclosed acquisition of Cocoon, a leave management technology company, and Cocoon became a wholly owned subsidiary of TriNet. The acquisition strengthens TriNet’s leave of absence offering with compliance-first solutions and AI-enabled workflows for SMB employers and their employees.
Neurocrine Biosciences entered into a definitive agreement to acquire Soleno Therapeutics in an all-cash transaction valued at approximately $2.9 billion. The deal adds Soleno’s first-in-class therapy VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome to Neurocrine’s commercial portfolio, and is expected to close within 90 days subject to customary conditions and regulatory approvals.
APM Group, a global provider of health and human services, announced that it has joined with occupational health provider WorkCare. The acquisition brings together the companies’ shared commitments to improving outcomes through integrated workforce health solutions, with WorkCare continuing to operate with its existing teams and service delivery approach.
MedReview, a payment integrity solutions provider for health insurers, announced its acquisition of Vital Data Technology. Vital Data will operate as a wholly-owned subsidiary, adding its AI-driven payer workflow and member outcome-focused analytics platform (Affinitē) to MedReview’s payer solution suite.
Collectly, an AI-powered patient financial experience platform for healthcare providers, acquired Pledge Health, an AI automation company focused on pre-service patient financial workflows. The deal adds an AI workflow engine to automate high-friction tasks such as coverage verification, cost estimates, financial clearance, and payment setup within Collectly’s end-to-end platform.
Reveam announced the acquisition of AcceleRAD Technologies, a global supplier of high-performance accelerator systems. The deal will make AcceleRAD a wholly owned subsidiary and expand Reveam’s engineering/manufacturing capabilities to scale its Electronic Cold-Pasteurization (ECP) food safety technology and extend accelerator applications into new industrial sectors.
MedImpact Holdings, Inc. announced the acquisition of two employer insurance and risk management firms: MHW Benefit Partners (formerly SRS Benefit Partners) and MSL Captive Solutions. The deals expand MedImpact’s portfolio of modular care and coverage options for small and mid-sized employers by adding captive program formation and medical stop-loss capabilities.
Gyre Therapeutics has completed its acquisition of Cullgen Inc. in an all-stock transaction valued at approximately $300 million. The deal creates a fully integrated U.S.- and China-based biopharmaceutical company focused on fibrosis and inflammatory diseases, combining Gyre’s commercial asset ETUARY with Cullgen’s targeted protein degrader (TPD) and degrader-antibody conjugate (DAC) platform and pipeline.
Complete Genomics entered into a definitive agreement to be acquired by Swiss Rockets AG, subject to customary closing conditions and approval by MGI shareholders. Swiss Rockets will own 100% of Complete Genomics and have sole control, while Complete Genomics continues operating as a U.S.-based company with its management team retaining responsibility for day-to-day operations and customer relationships.
Gilead Sciences entered into a definitive agreement to acquire Arcellx for $115 per share in cash plus a $5 per share contingent value right, implying an equity value of about $7.8 billion. The deal was completed on April 27, 2026, with Arcellx becoming a wholly owned subsidiary and full control of anito-cel and Arcellx’s D-Domain CAR technology platform.
Danaher has completed its acquisition of Masimo Corporation, a specialty diagnostics provider focused on pulse oximetry and patient monitoring solutions primarily used in acute care settings. Masimo will become a wholly-owned subsidiary of Danaher and continue operating under the Masimo brand as a stand-alone operating company within Danaher’s Diagnostics segment.
Full Export
Get the full acquisitions list for this page as CSV + XLSX.
Find buyers actively acquiring healthcare services companies.
Recent transactions include specialty care partnerships and acquisitions, infusion care expansion, clinical research organization acquisitions, and platform deals tied to patient activation, diagnostics, and oncology monitoring.
You’ll see a mix of outright acquisitions, mergers (including company renaming after closing), and partnership arrangements where minority investors remain involved.
The transactions listed are tied to California, United States locations in the deal descriptions, but some buyers (and related corporate entities) are not described as California-based in the provided facts.
No. For example, the acquisition of Clinical Trials Research (CTR) by Headlands Research notes that financial terms were not disclosed, while other deals specify amounts or per-share consideration.